The Journal of Immunology, Vol 151, Issue 3 1410-1418, Copyright © 1993 by American Association of Immunologists

ARTICLES

Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA

BH O'Neil, Y Kawakami, NP Restifo, JR Bennink, JW Yewdell and SA Rosenberg
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

To detect shared human melanoma Ag that are recognized by HLA-A2 restricted, melanoma-specific CTL derived from tumor infiltrating lymphocytes, we have developed a convenient method to insert and express foreign HLA genes capable of presenting Ag on target cell lines. Seventeen melanoma cell lines and 11 nonmelanoma cell lines were infected with recombinant vaccinia virus containing the HLA-A2.1 gene. Infection by the vaccinia virus resulted in expression of functional HLA-A2 molecules on the cell surface of virtually 100% of infected cells within a 3.5-h period. The results showed that 11 of 17 (65%) naturally HLA-A2- melanoma cell lines were specifically lysed by the HLA-A2-restricted, melanoma-specific TIL after infection with the vaccinia-HLA-A2.1 virus. None of the nine human nonmelanoma cell lines tested (three colon cancer, four breast cancer, or two immortalized non- tumor cell lines) or two murine melanoma cell lines were lysed by the HLA-A2-restricted TIL after vaccinia-HLA-A2.1 infection. Coinfection of the vaccinia virus containing the beta 2-microglobulin gene with the vaccinia-HLA-A2.1 virus increased the surface expression of HLA-A2 and subsequent lysis by melanoma-specific tumor infiltrating lymphocytes. With this new method we could extend previous findings demonstrating that shared melanoma Ag recognized by HLA-A2-restricted tumor infiltrating lymphocytes exist among melanoma cells from different patients regardless of HLA type. These Ag represent excellent candidates for the development of vaccines to induce T cell responses for the immunotherapy of patients with melanoma.

This article has been cited by other articles:

				T. D. Schell, J. D. Lippolis, and S. S. Tevethia Cytotoxic T Lymphocytes from HLA-A2.1 Transgenic Mice Define a Potential Human Epitope from Simian Virus 40 Large T Antigen Cancer Res., February 1, 2001; 61(3): 873 - 879. [Abstract] [Full Text]

				J. Dannull, P.-A. Diener, L. Prikler, G. Fürstenberger, T. Cerny, U. Schmid, D. K. Ackermann, and M. Groettrup Prostate Stem Cell Antigen Is a Promising Candidate for Immunotherapy of Advanced Prostate Cancer Cancer Res., October 1, 2000; 60(19): 5522 - 5528. [Abstract] [Full Text]

				F. Housseau, R. K. Bright, T. Simonis, M. I. Nishimura, and S. L. Topalian Recognition of a Shared Human Prostate Cancer-Associated Antigen by Nonclassical MHC-Restricted CD8+ T Cells J. Immunol., December 1, 1999; 163(11): 6330 - 6337. [Abstract] [Full Text] [PDF]

				S. P. Lee, C. M. Constandinou, W. A. Thomas, D. Croom-Carter, N. W. Blake, P. G. Murray, J. Crocker, and A. B. Rickinson Antigen Presenting Phenotype of Hodgkin Reed-Sternberg Cells: Analysis of the HLA Class I Processing Pathway and the Effects of Interleukin-10 on Epstein-Barr Virus-Specific Cytotoxic T-Cell Recognition Blood, August 1, 1998; 92(3): 1020 - 1030. [Abstract] [Full Text] [PDF]

				M. P. Bettinotti, C. J. Kim, K.-H. Lee, M. Roden, J. N. Cormier, M. Panelli, K. K. Parker, and F. M. Marincola Stringent Allele/Epitope Requirements for MART-1/Melan A Immunodominance: Implications for Peptide-Based Immunotherapy J. Immunol., July 15, 1998; 161(2): 877 - 889. [Abstract] [Full Text] [PDF]

				M. Theobald, J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes J. Exp. Med., March 3, 1997; 185(5): 833 - 842. [Abstract] [Full Text] [PDF]